Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that MIV-247 has been selected as a candidate drug (CD) from its cathepsin S...
Read moreStockholm, Sweden – Medivir AB (OMX:MVIR) announced further results from the phase I clinical study on the investigational cathepsin K inhibitor...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) announced that data will be presented on the investigational protease inhibitor simeprevir for the...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) today reports that Janssen Pharmaceutical R&D Ireland (Janssen) has been informed by the Japanese...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) today announced that a Capital Markets Day will be arranged for journalists, analysts and...
Read moreUnder the terms of the agreement, Ferrer grants to Medivir the exclusive rights to promote, market, sell and distribute ADASUVE in...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) On February 22, 2013 Janssen submitted a regulatory application to the Japanese Ministry of...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) today announced that it has discontinued the development of its hepatitis B compound MIV-210...
Read moreStockholm, Sweden — Medivir AB (OMX: MVIR) today announced interim results from the second Cohort in the ongoing COSMOS study evaluating...
Read moreQ2 2013 (April – June) Remaining Group operations, excluding Cross Pharma Net turnover totalled SEK 40.7 million (SEK 39.0 m). The...
Read more